Calendar

Week of Apr 20, 2026

Apr 24, 2026patent expiry91d agoDaiichi Sankyo Co Ltd — laninamivir (Constraining Patent Expiry (Japan))laninamivir

Therapy area: Infectious Disease, Respiratory. Indication: Asthma, Influenzavirus A Infections, Influenzavirus B Infections

full page →laninamivir →source: globaldata

Apr 24, 2026patent expiry91d agoEisai Co Ltd — lenvatinib mesylate (Constraining Patent Expiry (US))lenvatinib mesylate

Therapy area: Gastrointestinal, Infectious Disease, Oncology. Indication: Acral Lentiginous Melanoma, Adenocarcinoma Of The Gastroesophageal Junction, Adenoid Cystic Carcinoma (ACC), Adrenocortical Carcinoma (Adrenal Cortex Cancer), Anaplastic Thyroid Cancer, Bile Duct Cancer (Cholangiocarcinoma), Bladder Cancer, Breast Cancer, Colorectal Cancer, Cutaneous Squamous Cell Carcinoma (cSCC), Endometrial Cancer, Ependymoma, Epithelial Ovarian Cancer, Esophageal Squamous Cell Carcinoma (ESCC), Ewing S

full page →lenvatinib mesylate →source: globaldata

Apr 24, 2026drug expiry91d agoDaiichi Sankyo Co Ltd — laninamivir (Drug Expiry (Japan))laninamivir

Therapy area: Infectious Disease, Respiratory. Indication: Asthma, Influenzavirus A Infections, Influenzavirus B Infections

full page →laninamivir →source: globaldata

Apr 24, 2026drug expiry91d agoEisai Co Ltd — lenvatinib mesylate (Drug Expiry (US))lenvatinib mesylate

full page →lenvatinib mesylate →source: globaldata

Apr 24, 2026phase 1 results91d agoWroclaw Medical University — viral-specific T-cells (Phase I Trial Results)viral-specific T-cells

Therapy area: Hematological Disorders, Infectious Disease, Oncology. Indication: Aplastic Anemia, Cytomegalovirus (HHV-5) Infections, Hemophagocytic Lymphohistiocytosis, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Refractory Acute Myeloid Leukemia, Viral Infections

full page →viral-specific T-cells →source: globaldata

Apr 24, 2026phase iv trial initiation91d agoDr Rajendra Prasad Centre for Ophthalmic Sciences — carboxymethylcellulose (Phase IV Trial Initiation)carboxymethylcellulose

Therapy area: Ophthalmology. Indication: Keratoconjunctivitis Sicca (Dry Eye), Unspecified Ophthalmological Disorders

full page →carboxymethylcellulose →source: globaldata

Apr 25, 2026phase 0 trial completion90d agoExegenesis Bio Inc — EXG-202 (Phase 0 Trial Completion)EXG-202

Therapy area: Ophthalmology. Indication: Age Related Macular Degeneration, Macular Degeneration, Wet (Neovascular / Exudative) Macular Degeneration

full page →EXG-202 →source: globaldata

Apr 25, 2026phase 1 completion90d agoChangchun Bcht Biotechnology Co Ltd — influenza (trivalent, split virion) vaccine (Phase I Trial Completion)influenza (trivalent, split virion) vaccine

Therapy area: Infectious Disease. Indication: Unspecified Influenza Virus Infections

full page →influenza (trivalent, split virion) vaccine →source: globaldata

Apr 25, 2026phase 1 completion90d agoShenzhen Salubris Pharmaceuticals Co Ltd — (alisartan calcium + amlodipine besylate + sacubitril) (Phase I Trial Completion)(alisartan calcium + amlodipine besylate + sacubitril)

Therapy area: Cardiovascular. Indication: Hypertension

full page →(alisartan calcium + amlodipine besylate + sacubitril) →source: globaldata

Apr 25, 2026phase 2 completion90d agoTamilnadu Government Dental College and Hospital — Gengigel (Phase II Trial Completion)Gengigel

Therapy area: Infectious Disease. Indication: Dental Abscess

full page →Gengigel →source: globaldata

Apr 25, 2026phase 2 initiation90d agoGSK plc — dostarlimab (Phase II Trial Initiation)dostarlimab

Therapy area: Infectious Disease. Indication: Hepatitis B

full page →dostarlimab →source: globaldata

Apr 26, 2026phase 1 2 completion89d agoMahatma Gandhi Ayurved College Hospital and research centre — ayurvedic medicine (Phase I/II Trial Completion)ayurvedic medicine

Therapy area: Cardiovascular. Indication: Thrombophlebitis

full page →ayurvedic medicine →source: globaldata

Apr 26, 2026phase 2 completion89d agoCentral Council for Research in Unani Medicine — unani medicine (Phase II Trial Completion)unani medicine

Therapy area: Ophthalmology. Indication: Asthenopia (Eye Strain), Keratoconjunctivitis Sicca (Dry Eye), Unspecified Ophthalmological Disorders

full page →unani medicine →source: globaldata

Apr 26, 2026phase 2 completion89d agoBangalore Medical College and Research Institute — bupivacaine (Phase II Trial Completion)bupivacaine

Therapy area: Infectious Disease, Women's Health. Indication: Labor And Delivery, Pregnancy, Puerperal Infection

full page →bupivacaine →source: globaldata

Apr 26, 2026phase 2 initiation89d agoBeijing Chao-Yang Hospital — oxymetazoline hydrochloride (Phase II Trial Initiation)oxymetazoline hydrochloride

Therapy area: Ophthalmology. Indication: Blepharitis, Ptosis

full page →oxymetazoline hydrochloride →source: globaldata

Apr 26, 2026phase 2 results89d agoMinistry of Education University and Research, Italy — artichoke (Phase II Trial Results)artichoke

Therapy area: Cardiovascular, Gastrointestinal. Indication: Endothelial Dysfunction, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD or NAFLD)

full page →artichoke →source: globaldata

Apr 26, 2026phase 3 completion89d agoHubei Provincial Center for Disease Control and Prevention — rabies vaccine (Phase III Trial Completion)rabies vaccine

Therapy area: Infectious Disease. Indication: Rabies

full page →rabies vaccine →source: globaldata

Apr 26, 2026phase 3 completion89d agoTehran University of Medical Sciences — diltiazem (Phase III Trial Completion)diltiazem

Therapy area: Cardiovascular. Indication: Unspecified Cardiovascular Disorders

full page →diltiazem →source: globaldata

Week of Apr 27, 2026

Apr 27, 2026phase 1 initiation88d agoNational Institute of Neurological Disorders and Stroke — pembrolizumab (Phase I Trial Initiation)pembrolizumab

Therapy area: Infectious Disease. Indication: Coronavirus Disease 2019 (COVID-19), Post-Acute Sequelae of COVID 2019 (PASC or Long COVID)

full page →pembrolizumab →source: globaldata

Apr 27, 2026constraining patent expiry europe

← prev

page 1 of 2

Week of Apr 20, 2026

Week of Apr 27, 2026